Long-term Episealer® clinical results to be presented at international congress
Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “SURVIVORSHIP AND CLINICAL OUTCOMES OF A NOVEL PERSONALIZED METAL IMPLANT FOR THE TREATMENT OF CARTILAGE LESIONS OF THE KNEE”, by Dr Francesca de Caro has been accepted for presentation at the ISAKOS (International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine) congress in Munich, Germany, on June 8-11, 2025. The abstract with up to 10 years’ follow-up reports on high implant survival and good clinical outcomes for 34 patients who were treated with Episurf Medical’s individualised implant Episealer® Knee, as treatment for chondral and osteochondral defects in the knee. The patients were treated during 2013 – 2023 at AZ Monica Hospital, Antwerp, Belgium.
“The ISAKOS meeting is one of the major international meetings for surgeons active within joint preservation. We are proud to see that our technology continues to get attention and has become a recurring topic at scientific meetings. We also appreciate the engagement from independent study groups. The long-term results they present, with up to 10 years’ follow-up, makes our treatment option attractive now also to arthroplasty surgeons, who are used to the long-term results that previously only were available for larger prostheses”, says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEST on 5 June 2025.
Tags: